{
    "clinical_study": {
        "@rank": "20054", 
        "acronym": "DEFINE", 
        "arm_group": [
            {
                "arm_group_label": "FMD subjects", 
                "description": "patients who fulfill standard diagnostic criteria for FMD"
            }, 
            {
                "arm_group_label": "Healthy control subjects", 
                "description": "preferably healthy relative of FMD patient"
            }
        ], 
        "biospec_descr": {
            "textblock": "Fibroblasts and other cell lines generated under this protocol and all blood-derived\n      specimens (plasma, serum, DNA) will be kept indefinitely in a secure clinical database or\n      bio-repository (as appropriate)."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the functional, molecular and genetic profile of\n      fibroblasts from Fibromuscular Dysplasia (FMD) patients. This cellular profile will be\n      compared against the profile of fibroblasts obtained from age- and gender-matched healthy\n      control subjects. This cellular data will be supplemented by a detailed clinical history and\n      evaluation, assessment of circulating protein and cytokine levels in FMD versus healthy\n      control subjects, and DNA sequencing aiming to define the causative genetic mutation(s)."
        }, 
        "brief_title": "Defining the Basis of Fibromuscular Dysplasia (FMD)", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Fibromuscular Dysplasia", 
        "condition_browse": {
            "mesh_term": "Fibromuscular Dysplasia"
        }, 
        "detailed_description": {
            "textblock": "Specific aims\n\n        -  Specific aim 1: To establish a library of fibroblasts, DNA, plasma and serum from\n           patients with FMD and unaffected healthy control subjects.\n\n        -  Specific aim 2: To compare the in vitro characteristics of fibroblasts from FMD\n           patients and healthy control subjects.\n\n        -  Specific aim 3: To define and compare the genetic (DNA sequencing) and circulating\n           cytokine profile of FMD versus healthy control subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients of any age and freely willing to participate. For patients < 18 years of age\n             consent will be via parents.\n\n          -  Fluency in either English or Spanish.\n\n          -  Signed, informed consent\n\n          -  For FMD subjects - a clinical diagnosis of FMD, with fulfillment of standard\n             diagnostic criteria.\n\n          -  For healthy controls - no clinical features of FMD, and absence of any major ongoing\n             systemic disease including any condition requiring hospitalization, immune\n             suppression, intravenous or injected medications or that result in functional\n             impairment in the performance of activities of daily living. Where possible, healthy\n             controls will be unaffected family members. Healthy controls will be matched to\n             enrolled FMD patients on the basis of gender and approximate age (within a 5 year\n             window of another FMD subject).\n\n        Exclusion Criteria:\n\n          -  Patients who have co-morbidities which reduces life expectancy to one year.\n\n          -  Patients with any solid organ or hematological transplantation, or those in whom\n             transplantation is considered.\n\n          -  Active autoimmune disease.\n\n          -  Illicit drug use.\n\n          -  HIV positive.\n\n          -  Prior malignancy.\n\n          -  Any other form of vascular disease, including coronary artery disease or peripheral\n             vascular disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Will enroll up to 200 FMD patients and controls at the Mount Sinai Hospital.  Healthy\n        controls will also be recruited to this study."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967511", 
            "org_study_id": "GCO 13-1118"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cross-sectional study", 
            "Fibromuscular dysplasia", 
            "Fibroblast", 
            "FMD"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "contact": {
                "email": "annette.king@mountsinai.org", 
                "last_name": "Annette King, ANP", 
                "phone": "212-241-9454"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Icahn School of Medicine at Mount Sinai"
            }, 
            "investigator": {
                "last_name": "Jason Kovacic, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study", 
        "overall_contact": {
            "email": "jason.kovacic@mountsinai.org", 
            "last_name": "Jason Kovacic, MD, PhD", 
            "phone": "212-241-4059"
        }, 
        "overall_contact_backup": {
            "email": "jeffrey.olin@mountsinai.org", 
            "last_name": "Jeffrey Olin, DO"
        }, 
        "overall_official": [
            {
                "affiliation": "Mount Sinai School of Medicine", 
                "last_name": "Jason Kovacic, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Mount Sinai School of Medicine", 
                "last_name": "Jeffrey Olin, DO", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Phenotypic characterization of fibroblasts from FMD patients versus healthy controls", 
            "measure": "Fibroblasts phenotype", 
            "safety_issue": "No", 
            "time_frame": "single time point at study enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967511"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To define and compare the genetic (DNA sequencing) profile of FMD versus healthy control subjects", 
                "measure": "DNA sequencing", 
                "safety_issue": "No", 
                "time_frame": "single time point at study enrollment"
            }, 
            {
                "description": "To define and compare the circulating cytokine profile of FMD versus healthy control subjects.", 
                "measure": "Circulating cytokine", 
                "safety_issue": "No", 
                "time_frame": "single time point at study enrollment"
            }
        ], 
        "source": "Mount Sinai School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}